Supporting Clinical Research in Schizophrenia

Advancing Scientific Innovation in Schizophrenia

VeraSci brings decades of experience and deep scientific expertise to clinical trials in schizophrenia. Schizophrenia is a complex, multi-faceted neuropsychiatric disorder and one of the leading causes of functional disability in the world. In addition to targeting the characteristic positive symptoms (e.g., delusions, hallucinations) of schizophrenia, many trials are testing novel agents that target other functionally disabling aspects of this disorder, including negative symptoms and cognitive impairment. VeraSci has been an industry leader in supporting trials aimed at enhancing cognitive impairment associated with schizophrenia through implementation of the gold-standard MATRICS Consensus Cognitive Battery (MCCB) and key co-primary functional capacity outcome measures. We are also leading trials aimed at improving negative symptoms (e.g., avolition, affective flattening) using gold-standard rating scales, as well as cutting-edge interview- and performance-based measures.

Our highly experienced team brings decades of clinical research and treatment experience to support state-of-the art clinical trials in schizophrenia. We offer comprehensive start-to-finish services for clinical trials including trial design and regulatory strategy consultation, novel method development, implementation of rigorous assessment and quality assurance procedures, linguistics for multi-national trials, and interpretation of trial results.

Richard Keefe, PhD

Co-Founder & CEO

William P. Horan, PhD

VP, Clinical Science

Victoria Villalta-Gil, PhD

Clinical Scientist

Dependable Solutions for Global Clinical Trials

VeraSci is not just there in the beginning; we take care of your study objectives and data throughout the entire trial. As your partner, we leverage experience gained through hundreds of trials and ensure the highest quality data, all while anticipating any issues that can derail or delay your study before they arise.

 

We provide expert solutions in:

Select Endpoints & Assessments for Schizophrenia

Clinical

AIMS- Abnormal Involuntary Movement Scale
BARS-
Barnes Akathisia Rating Scale
C-SSRS-
Columbia Suicide Severity Rating Scale
CAINS-
Clinical Assessment Interview for Negative Symptoms
CDSS-
Calgary Depression Scale for Schizophrenia
CGI-S-
Clinical Global Impression – Severity of Illness
MINI-
Mini International Neuropsychiatric Interview
NSA-16-
Negative Symptom Assessment – 16 Items
PANSS-
Positive and Negative Syndrome Scale
SAS-
Simpson-Angus Scale

Cognitive

BAC- Brief Assessment of Cognition
BET- Balloon Effort Test
MCCB- MATRICS Consensus Cognitive Battery
SCoRS- Schizophrenia Cognition Rating Scale

Functional

UPSA- UCSD Performance-Based Skills Assessment
UPSA-B- UCSD Performance-Based Skills Assessment Abbreviated Version
VRFCAT- Virtual Reality Functional Capacity Assessment Tool